Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Targeting protein kinases in central nervous system disorders Chico LK; Van Eldik LJ; Watterson DMNat Rev Drug Discov 2009[Nov]; 8 (11): 892-909Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues associated specifically with CNS drug discovery. However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclinical and clinical development. We review candidate compounds and discuss selected CNS protein kinases that are emerging as important therapeutic targets. In addition, we analyse trends in small-molecule properties that correlate with key challenges in CNS drug discovery, such as blood-brain barrier penetrance and cytochrome P450-mediated metabolism, and discuss the potential of future approaches that will integrate molecular-fragment expansion with pharmacoinformatics to address these challenges.|Animals[MESH]|Blood-Brain Barrier/metabolism[MESH]|Central Nervous System Diseases/*drug therapy/enzymology/physiopathology[MESH]|Clinical Trials as Topic[MESH]|Drug Delivery Systems[MESH]|Drug Design[MESH]|Drug Evaluation, Preclinical[MESH]|Humans[MESH]|Protein Kinase Inhibitors/metabolism/pharmacokinetics/*therapeutic use[MESH]|Protein Kinases/*drug effects/metabolism[MESH] |
